GlassScriptPhysician profile
Erin Fransen
NPI 1073248159
$13,732.32
in general payments reported to CMS, 2019-2025
30 companies · $2,284 in 2025
The $2,284 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,932 · 2023: $4,678 · 2024: $4,839 · 2025: $2,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,676.57 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,766.22 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,667.71 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,607.55 | 2022-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Abbvie INC. | $1,176.18 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $1,175.23 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $904.44 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $886.38 | 2022-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $746.55 | 2022-2025 | Qelbree |
| Lundbeck LLC | $679.69 | 2022-2025 | Rexulti, Brintellix |
| Axsome Therapeutics, INC. | $643.64 | 2022-2025 | Auvelity, Sunosi |
| Corium, LLC | $472.47 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $367.10 | 2022-2025 | Fanapt, Hetlioz |
| Livanova USA, INC. | $280.21 | 2023-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Takeda Pharmaceuticals U.S.A., INC. | $185.23 | 2022-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $181.91 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $181.79 | 2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $132.75 | 2022-2024 | Quviviq |
| Eisai INC. | $117.12 | 2023 | |
| Azurity Pharmaceuticals, INC. | $112.41 | 2023-2024 | Horizant, Horizant |
| E.R. Squibb & Sons, L.L.C. | $92.09 | 2024 | Cobenfy |
| Bausch Health US, LLC | $81.46 | 2022-2025 | Wellbutrin |
| Acadia Pharmaceuticals INC | $79.41 | 2022-2025 | Nuplazid |
| Orexo US, INC. | $40.49 | 2022-2023 | Zubsolv |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $30.75 | 2024 | Rejoyn |
| Biogen, INC. | $28.22 | 2024 | |
| Indivior INC. | $23.16 | 2024 | Sublocade |
| Noven Therapeutics, LLC | $19.54 | 2024 | Secuado, Xelstrym |
| Luye Pharma (USA) LTD. | $19.06 | 2025 | Erzofri Extended-Release |
| Nobelpharma America, LLC | $17.46 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Fransen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.